Quotes

Company Overview

Financial Analysis

Main Composition Key Indicators Financial Statement

Multi-dimentional Analyses

Company Valuation Capital Tracking Short Selling Data

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

CEO： Goldsmith Ph.D., Mark A.

Market： NASDAQ

Hot List

TradeSearchNews

SymbolLatest price%Chg

Moomoo > Quotes > RVMD Revolution Medicines > Detailed Quotes

RVMD Revolution Medicines

15.890+0.290+1.86%

Close 05/26 20:00 ET

High

16.110

Open

15.700

Turnover

6.14M

Low

15.340

Pre Close

15.600

Volume

386.27K

Intraday

Price Forecast

No Data

RVMD Revolution Medicines

News

Comment

News

Announcement

All

Earnings Report

Related Transactions

Changes In Ownership

Major Events

Other